/PRNewswire/ A latest research report [110+] pages with 360-Degree visibility, titled "Human Platelet Lysate Market Share, Size, Trends, Industry Analysis.
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH
iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.
Purpose: Corneal perforation is a clinical emergency that can result in blindness. Currently corneal perforations are treated either by cyanoacrylate glue which is toxic to corneal cells, or by using commercial fibrin glue for small perforations. Both methods use manual delivery which lead to uncontrolled application of the glues to the corneal surface. Therefore, there is a need to develop a safe and effective alternative to artificial adhesives.Methods: Previously, our group developed a transparent human platelet lysate (hPL)-based biomaterial that accelerated corneal epithelial cells healing in vitro. This biomate-rial was further characterized in this study using rheometry and adhesive test, and a two-component delivery system was developed for its application. An animal trial (5 New Zealand white rabbits) to compare impact of the biomaterial and cyanoacrylate glue (control group) on a 2 mm perforation was conducted to evaluate safety and efficacy.Results: The hPL-based biomaterial
Albany NY, United States: Transparency Market Research finds that players in the global Platelet Incubator Market are ramping their investments in several expansion strategies to gain a competitive edge.